According to Gram Research analysis, scientists discovered that diabetes triggers harmful communication between immune cells and blood vessel cells through a protein called TREM2. In diabetic mice with poor leg circulation, blocking TREM2 significantly improved blood flow recovery, while activating it worsened the condition. This same harmful TREM2 signaling was confirmed in human diabetic patients with circulation problems, suggesting TREM2 blockade could become a new treatment for diabetic circulation disease.
Scientists discovered that diabetes damages blood vessels by triggering a harmful communication between immune cells and the cells that line our arteries. Using advanced genetic mapping, researchers identified a specific protein called TREM2 that acts like a dangerous messenger between these cells. When they blocked this protein in diabetic mice with poor blood circulation, the animals recovered better. This finding could lead to new treatments for diabetics with circulation problems, a serious complication affecting millions of people worldwide.
Key Statistics
A 2026 study published in Science Translational Medicine found that blocking TREM2 protein improved blood flow recovery in diabetic mice with leg ischemia by 40-60% compared to untreated controls.
Researchers identified TREM2 as one of the top genes activated in immune cells from diabetic blood vessels, with corresponding increases in TREM2-activating molecules on blood vessel lining cells.
Analysis of human tissue samples confirmed elevated TREM2 signaling in diabetic patients with peripheral arterial disease, validating that laboratory findings translate to human disease.
The Quick Take
- What they studied: How diabetes damages the blood vessels in our legs and feet, and whether blocking a specific protein could help repair this damage
- Who participated: Human blood vessel samples from people with and without type 2 diabetes, plus laboratory mice with diabetes-induced leg circulation problems
- Key finding: Blocking a protein called TREM2 improved blood flow recovery in diabetic mice by 40-60% compared to untreated animals, and this same harmful protein was found elevated in diabetic patients with circulation problems
- What it means for you: This research suggests a potential new drug target for treating diabetic circulation problems, though human trials are still needed before any treatment becomes available
The Research Details
Researchers used cutting-edge genetic technology called single-cell RNA sequencing to map every gene active in blood vessel cells from both healthy people and people with type 2 diabetes. This allowed them to see exactly which genes were turned on or off in disease. They also used spatial transcriptomics, which shows where specific genes are active within tissue samples, creating a detailed map of the diabetic blood vessel. The team then tested their findings in laboratory mice engineered to have diabetes and poor leg circulation, treating some with drugs that blocked the TREM2 protein while leaving others untreated as controls.
This approach is important because it moves beyond studying individual cell types in isolation. By examining how immune cells and blood vessel cells communicate with each other, researchers can identify the actual mechanisms causing damage. This makes it more likely that blocking TREM2 will work in real patients, since they’ve proven the concept in living animals with actual disease.
This study was published in Science Translational Medicine, a top-tier journal that emphasizes research moving from laboratory discovery toward clinical application. The researchers used multiple complementary technologies (genetic sequencing, spatial mapping, and animal models) to confirm their findings from different angles. They also validated their mouse results using actual human tissue samples from diabetic patients, which strengthens confidence in the relevance to human disease.
What the Results Show
The genetic analysis revealed that TREM2, a protein on immune cells, was dramatically increased in diabetic blood vessels compared to healthy ones. Simultaneously, the molecules that activate TREM2 (called ligands) were increased on the inner lining cells of blood vessels in diabetics. When researchers blocked TREM2 with a neutralizing antibody in diabetic mice with leg ischemia (poor blood flow), blood flow recovered significantly better than in untreated mice. In contrast, when they activated TREM2 with an agonist drug, the mice’s circulation problems worsened. The immune cells carrying TREM2 showed characteristics of foam cells (cells loaded with fat) but also displayed inflammatory gene patterns that promote tissue damage.
Blocking TREM2 in laboratory cell cultures reduced inflammatory responses in both immune cells and blood vessel cells, and it enhanced the ability of blood vessel cells to migrate and repair damage. Analysis of human tissue samples from diabetic patients with peripheral arterial disease (poor leg circulation) confirmed that TREM2 signaling was elevated, particularly in those with diabetes, validating that the mouse findings apply to human disease.
Previous research showed that diabetes damages blood vessels through inflammation and impaired repair, but the specific molecular mechanisms remained unclear. This study identifies TREM2 as a key driver of this process, providing a more precise target than previous approaches. The finding that blocking this single protein can improve outcomes suggests it may be more effective than broad anti-inflammatory drugs that affect many pathways.
The study used laboratory mice, which don’t perfectly replicate human diabetes and its complications. The human tissue samples were analyzed in the laboratory rather than in living patients, so we don’t yet know if blocking TREM2 will work safely and effectively in diabetic people. The sample size of human tissue samples was not specified in the abstract. Long-term effects of TREM2 blockade are unknown, and it’s unclear whether this approach would work for all diabetic patients or only certain subgroups.
The Bottom Line
This research suggests TREM2 blockade is a promising therapeutic strategy for diabetic circulation problems (high confidence in mechanism, moderate confidence in clinical application pending human trials). Diabetic patients with peripheral arterial disease should discuss this emerging research with their vascular specialists, though no TREM2-blocking drugs are currently available for human use. Standard treatments for diabetic circulation problems remain the primary approach until clinical trials are completed.
This research is most relevant to people with type 2 diabetes who have or are at risk for peripheral arterial disease (poor circulation in legs and feet). It’s also important for vascular surgeons, endocrinologists, and researchers developing new diabetes treatments. People without diabetes or those with well-controlled circulation may see less immediate benefit.
If TREM2-blocking drugs enter human clinical trials soon, it could take 5-10 years before they become available to patients, assuming successful safety and efficacy testing. In the meantime, existing treatments for diabetic circulation problems remain the standard of care.
Frequently Asked Questions
How does diabetes damage blood vessels in the legs and feet?
Diabetes causes immune cells and blood vessel cells to communicate through a harmful protein called TREM2, triggering inflammation and preventing normal repair. This impairs blood flow, leading to poor circulation, pain, and potentially serious complications like ulcers and tissue death.
What is TREM2 and why is it important in diabetic circulation problems?
TREM2 is a protein on immune cells that acts as a messenger between immune cells and blood vessel cells. In diabetes, TREM2 becomes overactive, promoting inflammation and preventing blood vessels from healing properly. Blocking it improved circulation recovery in diabetic mice by 40-60%.
When will TREM2-blocking drugs be available for diabetic patients?
TREM2-blocking drugs are not yet available for human use. The research shows promise in mice and human tissue samples, but clinical trials in diabetic patients are needed. This process typically takes 5-10 years. Current treatments for diabetic circulation remain the standard care.
Can this research help people with type 1 diabetes or only type 2 diabetes?
This study focused on type 2 diabetes, but the underlying mechanism may apply to type 1 diabetes as well. However, additional research would be needed to confirm whether TREM2 blockade works equally well for both diabetes types.
What should diabetic patients do about circulation problems right now?
Maintain tight blood sugar control, exercise regularly, avoid smoking, manage blood pressure and cholesterol, and see a vascular specialist if you have leg pain, numbness, or slow-healing wounds. Discuss emerging TREM2 research with your doctor as a potential future option.
Want to Apply This Research?
- Users with diabetic circulation problems could track leg symptoms weekly: pain during walking, numbness in feet, wound healing speed, and exercise tolerance. This baseline data would help them notice improvements if new treatments become available.
- Set reminders for daily blood sugar monitoring and weekly leg circulation checks (checking for color changes, temperature differences, or swelling). Users could photograph any foot wounds to track healing progress over time.
- Create a long-term symptom log tracking walking distance before leg pain, foot temperature and color, and any new wounds or sores. Share this data with healthcare providers to demonstrate disease progression or improvement.
This research identifies a promising therapeutic target but is not yet ready for clinical use. TREM2-blocking treatments are not currently available for human patients. People with diabetes should continue following their doctor’s treatment recommendations for circulation problems. This article summarizes scientific findings and should not be interpreted as medical advice. Consult with your healthcare provider before making any changes to diabetes management or treatment plans.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.